Edwards Lifesciences Corporation (EW)
NYSE: EW · Real-Time Price · USD
77.68
+0.75 (0.97%)
At close: Aug 13, 2025, 4:00 PM
77.68
0.00 (0.00%)
Pre-market: Aug 14, 2025, 8:02 AM EDT
Edwards Lifesciences Revenue
Edwards Lifesciences had revenue of $1.53B in the quarter ending June 30, 2025, with 11.89% growth. This brings the company's revenue in the last twelve months to $5.69B, up 9.14% year-over-year. In the year 2024, Edwards Lifesciences had annual revenue of $5.44B with 8.57% growth.
Revenue (ttm)
$5.69B
Revenue Growth
+9.14%
P/S Ratio
8.07
Revenue / Employee
$359,816
Employees
15,800
Market Cap
45.61B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5.44B | 429.50M | 8.57% |
Dec 31, 2023 | 5.01B | 546.00M | 12.23% |
Dec 31, 2022 | 4.46B | -768.50M | -14.69% |
Dec 31, 2021 | 5.23B | 846.20M | 19.29% |
Dec 31, 2020 | 4.39B | 38.30M | 0.88% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
EW News
- 6 days ago - Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025 - Seeking Alpha
- 7 days ago - JenaValve Responds to FTC's Action Against Proposed Edwards Lifesciences Acquisition - GlobeNewsWire
- 7 days ago - FTC seeks to block Edwards Lifesciences' acquisition of JenaValve - Reuters
- 7 days ago - Edwards Lifesciences Comments on FTC's Action to Block Proposed Acquisition of JenaValve - Business Wire
- 7 days ago - Edwards Lifesciences Stock: Likely To See Sluggish Price Action Through 2027 - Benzinga
- 13 days ago - 10 stocks favored to gain up to 30% in a sector that has missed this year's rally - Market Watch
- 19 days ago - Edwards Lifesciences Lifts 2025 Outlook On Strong First Half Performance - Benzinga
- 19 days ago - Edwards Lifesciences Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Results - Benzinga